Premier Biomedical Competitors

Abacus Health Products (OTCMKTS:ABAHF) and Premier Biomedical (OTCMKTS:BIEI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Abacus Health Products and Premier Biomedical, as reported by MarketBeat.

Earnings & Valuation

This table compares Abacus Health Products and Premier Biomedical's top-line revenue, earnings per share and valuation.

Profitability

This table compares Abacus Health Products and Premier Biomedical's net margins, return on equity and return on assets.

Acreage (OTCMKTS:ACRGF) and Premier Biomedical (OTCMKTS:BIEI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Earnings & Valuation

This table compares Acreage and Premier Biomedical's top-line revenue, earnings per share and valuation.

Profitability

This table compares Acreage and Premier Biomedical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Acreage and Premier Biomedical, as reported by MarketBeat.

Acreage currently has a consensus target price of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher possible upside, equities research analysts plainly believe Acreage is more favorable than Premier Biomedical.

Summary

Acreage beats Premier Biomedical on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Premier Biomedical (OTCMKTS:BIEI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Applied Biosciences and Premier Biomedical's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Applied Biosciences and Premier Biomedical, as reported by MarketBeat.com.

Profitability

This table compares Applied Biosciences and Premier Biomedical's net margins, return on equity and return on assets.

Premier Biomedical (OTCMKTS:BIEI) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Premier Biomedical and Ayr Strategies' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Premier Biomedical and Ayr Strategies, as provided by MarketBeat.

Ayr Strategies has a consensus price target of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, analysts clearly believe Ayr Strategies is more favorable than Premier Biomedical.

Profitability

This table compares Premier Biomedical and Ayr Strategies' net margins, return on equity and return on assets.

Summary

Ayr Strategies beats Premier Biomedical on 2 of the 2 factors compared between the two stocks.

Premier Biomedical (OTCMKTS:BIEI) and Can B (NASDAQ:CANB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares Premier Biomedical and Can B's gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of current ratings and price targets for Premier Biomedical and Can B, as provided by MarketBeat.com.

Profitability

This table compares Premier Biomedical and Can B's net margins, return on equity and return on assets.

Premier Biomedical (OTCMKTS:BIEI) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Premier Biomedical and Cansortium, as provided by MarketBeat.com.

Cansortium has a consensus price target of $1.20, indicating a potential upside of 43.13%. Given Cansortium's higher probable upside, analysts plainly believe Cansortium is more favorable than Premier Biomedical.

Profitability

This table compares Premier Biomedical and Cansortium's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Premier Biomedical and Cansortium's gross revenue, earnings per share and valuation.

Summary

Cansortium beats Premier Biomedical on 2 of the 2 factors compared between the two stocks.